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We compared the long-term impact of 1- and 2-year screening mammography intervals using prognostic, screening, and outcome
information for women aged 50–74 years obtained from the Screening Mammography Program of British Columbia in two time
periods, prior to 1997 (policy of annual mammography) and after 1997 (biennial mammography). Survival was estimated for both
periods using a prognostic model and the expected rate of interval and screen-detected cancers. The likelihood of a screen-detected
cancer with annual screening was 2.32 per thousand screens and with biennial screening was 3.32 per thousand screens. The
prognostic profile of screen-detected cancers was better than that of interval cancers. Among both screen-detected and interval
cancers, the prognostic profiles with annual and biennial screening were similar. The estimated breast cancer-specific survival rates for
women undergoing annual and biennial screening mammography were 95.2 and 94.6% at 5 years, and 90.4 and 89.2% at 10 years,
respectively. Annual compared to biennial mammography was associated with a 1.2% increase in the estimated 10-year breast
cancer-specific survival for women aged 50–74 years, diagnosed with invasive breast cancer after screening programme attendance.
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Screening mammography reduces breast cancer mortality (Chu
et al, 1988; Chu and Connor, 1991; Nystrom et al, 1993;
Kerlikowske et al, 1995; Bjurstam et al, 1997; Alexander et al,
1999; Tabar et al, 2000; Black et al, 2002; Nystrom et al, 2002). A
meta-analysis of the randomised screening trials found equivalent
mortality reductions (23%) from approximate annual screening
compared to screening every 18–33 months (Kerlikowske et al,
1995). The only randomised trial to address the frequency of recall
between screens found that modelled 10- and 15-year breast cancer
survival was not significantly different for women undergoing
screening mammograms every year vs every 3 years (Breast
Screening Frequency Trial Group, 2002).
In British Columbia (BC), the third largest province in Canada
with a population of 4.2 million, the population-based Screening
Mammography Program (SMPBC) has provided bilateral two-view
mammograms to the asymptomatic female residents of BC, aged 40
and older, free of direct payment since 1988 (Olivotto et al, 2000).
In 1997, the SMPBC increased its recommended screening interval
for women aged 50–74 years from yearly to every 2 years.
We have examined the effect of this change in screening
frequency policy. As follow-up time since the policy change is too
short to demonstrate a difference in mortality, the impact on
breast cancer-specific survival was estimated by applying the
observed differences in the prognostic profile of cancers diagnosed
in women screened at different intervals to a prognostic prediction
model.
MATERIALS AND METHODS
This retrospective study modelled 10-year survival outcomes for
women, aged 50–74 years, screened annually and biennially
through the SMPBC. Two time periods were compared, prior to
1997 (‘annual’ screening group) and after 1997 (‘biennial’ screen-
ing group).
Data sources
Electronic records for participants in the SMPBC were collected
from the SMPBC database and the BC Cancer Registry, both of
which are administered through the BC Cancer Agency. The
SMPBC database contains demographic, prognostic, and outcome
information on all women screened through the programme and
maintains active follow-up to ascertain final pathology results for
women with abnormal screening mammograms. It is linked every
3 months with the BC Cancer Registry to identify all breast cancers
(screen-detected or otherwise) in screened women. The BC Cancer
Registry includes notifications of all cancer reported within the
province on either pathology reports or death certificates. The
capture rate for new cancers was 94% for the year 1999. Vital
status, date, and cause of death are obtained secondary to regular
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Health, Government of British Columbia.
For this study, a cancer was defined as an invasive epithelial
cancer of any histology or ductal carcinoma in situ (DCIS) (i.e.
sarcoma, lymphomas, phyllodes tumours, and lobular carcinoma
in situ lesions were excluded). Cancers were classified as screen-
detected if an abnormal screen led to a diagnostic sequence that
resulted in the detection of a breast cancer. All other cancers were
classified as interval cancers. Subjects were assumed to be at risk of
developing an interval cancer from the time of one screen until the
time of the first of either the subsequent screen, a diagnosis of an
interval cancer, death, or the date of December 31, 2001.
‘Prognostic’ and ‘screening’ data samples
Two overlapping sets of data were extracted. The ‘prognostic
sample’ consisted of all cases of unilateral breast cancer diagnosed
prior to January 1, 2002 in women ages 50–74 years, who had
attended the SMPBC. Prognostic and outcome information for
these cases was collected from the SMPBC database.
The ‘screening sample’ consisted of all women who received at
least one screen at ages 50–74 years, between 1988 and December
31, 2001. Each woman’s screening history was subdivided into
screening intervals, which started immediately after a screen and
terminated with the first of: another screen, death, diagnosis of
cancer or December 31, 2001. Since this was an analysis of recall
frequency, women diagnosed with cancer at their first screen were
excluded. Only screening intervals in which the woman was aged
50–74 years at the beginning were used.
‘Annual’ and ‘biennial’ screening frequency
Screening mammograms performed 10–14 months after the prior
screen and prior to January 1, 1997 were defined as ‘annual’
screens. Screening mammograms performed 20–28 months after
the prior screen and after December 31, 1997 were defined as
‘biennial’ screens. These time intervals were created because most
women did not return exactly 12 or 24 months after a previous
screen. These intervals of 10–14 months, pre-1997, and 20–28
months, post-1997, were chosen to maintain a period clinically
similar to the 1- and 2-year screening intervals of primary interest,
and to ensure a similar proportion of women returned for re-
screening (approximately 50% for each of the time periods
studied). Each screening interval was analysed independently, so
that women who had screens prior to and after 1997 could have
contributed screening intervals both to the annual and biennial
screening groups. As the SMPBC policy change from annual to
biennial screening was implemented in July 1997, the information
from the entire transition year of 1997 was not used.
Analytic schema/statistical methods
The following analytic approach was used:
(1) Prognostic model: A Cox proportional hazards model was
developed to predict breast cancer-specific survival based on
methods published by Tabar et al (1995) and Haybittle et al
(1982), using the ‘prognostic sample’ described above. Age,
tumour size (p9, 10–14, 15–19, 20–29, 30–49, 50þ mm,
unknown), nodal status (negative, positive, unknown) and
histologic grade (well, moderately, or poorly differentiated and
unknown) were examined as potential prognostic factors. As it
was assumed that the 10-year breast cancer survival from a
diagnosis of DCIS was 100% (Fisher et al, 1999; Julien et al,
2000), DCIS was not included in the model. Tests of
significance were based on the partial likelihood method.
The underlying hazard was estimated by the Breslow
estimator. Partial likelihood methods were used to generate
approximate confidence interval (Table 1).
(2) Prognostic distribution: The ‘screening sample’ described
above was used to identify cases of cancer falling into the
following four groups: (i) interval cases occurring up to 12
months after the previous screen in either the ‘annual’ or
‘biennial’ screening group, (ii) screen-detected cases occurring
10–14 months after the previous screen among those in the
‘annual’ screening group; and for those in the ‘biennial’
screening group, (iii) interval cases occurring 12–24 months
after the previous screen, and (iv) screen-detected cases
occurring 20–28 months after the previous screen (Table 2).
For each case in a group, the prognostic factors at presentation
were used to predict that woman’s survival using the pro-
gnostic model. These were then averaged across the members
of each group to provide an average predicted survival for the
particular group at 5 and 10 years (Table 3).
(3) Weighting: The distribution of screens (Table 4) and number
of cancer cases from the ‘screening sample’ described above
were then used to calculate the rates of cancer expected in
each of the above four groups (Table 5) Rates of interval
cancers were estimated using the Kaplan–Meier method
and rates of screen-detected cancers were calculated using
the observed proportions for the groups described earlier.
These were then used to create weights reflecting the
distribution of cancer cases by screening the frequency group,
detection method, and time of detection in the above four
groups.
(4) Prediction: The weights (from (3) above) were then applied to
the average group survival rates (from (2) above) to provide
the predicted 5- and 10-year survival rates.
RESULTS
Following 897216 screens provided to women aged 50–74 years
between 1988 and 2001 at the SMPBC, 5844 cases of invasive,
unilateral breast cancer were diagnosed. The distribution of
tumour size, grade, and lymph node status at diagnosis is given
Table 1 Distribution of tumour prognostic factors and corresponding
adjusted hazard ratio for breast cancer mortality for 5844 invasive breast
cancers diagnosed 1988–2001 in women undergoing screening mammo-
grams through SMPBC (prognostic sample)
Prognostic factor N (%) Hazard ratio (95% CI)
Tumour size (mm)
1–9 1163 (20) 1.0 —
10–14 1478 (25) 1.31 (1.20, 1.43)
15–19 1210 (21) 1.72 (1.45, 2.04)
20–29 1095 (19) 2.25 (1.74, 2.92)
30–49 480 (8) 2.95 (2.09, 4.16)
50+ 224 (4) 3.87 (2.51, 5.95)
Unknown 194 (3) 3.36 (2.43, 4.66)
Lymph node status
Negative 3608 (62) 1.0 —
Positive 1374 (23) 3.82 (2.91, 5.01)
Unknown 862 (15) 3.36 (2.43, 4.66)
Histologic grade
Well differentiated 1583 (27) 1.0 —
Moderately differentiated 2074 (36) 1.04 (0.71, 1.54)
Poorly differentiated 1295 (22) 3.42 (2.42, 4.83)
Unkown 892 (15) 3.36 (2.43, 4.66)
CI¼confidence interval.
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months. The overall survival curve for these cases is shown in
Figure 1.
In the Cox analysis of the prognostic sample, age was not
significantly associated with breast cancer-specific mortality
(P¼0.095), but size, grade and lymph node status were (Table 1).
The category ‘unknown’ was associated with a similarly poor
prognosis for all variables considered and was combined into a
composite category of ‘unknown for any variable’, which was a
Table 2 Distribution of prognostic factors among interval and screen-
detected cancers in the screening sample
Interval cancer (%)Screen-detected cancer (%)
Factor
p12
months
12–24
months
a
10–14
months
b
20–28
months
c
Total number of cases (n) 656 655 438 692
Tumour size (mm)
1–9 11 13 25 28
10–14 19 19 33 28
15–19 20 20 20 22
20–29 26 27 12 14
30–49 11 13 6 5
50+ 8 7 2 1
Unknown 5 3 2 2
Lymph node status
Negative 54 53 67 71
Positive 32 32 15 22
Unknown 14 14 18 7
Histologic grade
Well 21 21 24 34
Mod 32 32 47 32
Poor 31 31 22 14
Unknown 17 16 7 20
Unknown (size, node, or grade)
None 25 26 22 26
Any 75 74 78 74
aIncluding interval cancers diagnosed 20–28 months after a screen prior to January 1,
1997.
bPrior to January 1, 1997.
cAfter December 31, 1997.
Table 3 Estimated 5- and 10-year breast cancer specific-survival rates by
type of cancer and time from most recent mammogram to diagnosis
Estimated
5-year
survival
rate (%)
Estimated
10-year
survival
rate (%)
Screen-detected cancer at 10–14 months 96.0 91.8
Screen-detected cancer at 20–28 months 96.1 91.9
Interval cancer p12 months 92.7 85.7
Interval cancer 12–24 months 92.5 85.3
Table 4 Distribution of screening intervals for women, age 50–74 years
at time of an initial screen, who were re-screened prior to and after 1997
Date of screen Before 1997 (%) After 1997 (%)
Length of interval (months)
0–9 1459 (0.5) 38 (0.0)
10–14 ‘annual’ 188709 (68) 80767 (20)
14–19 49585 (18) 53908 (13)
20–28 ‘biennial’ 24940 (9) 208723 (52)
28+ 14459 (5) 58647 (15)
Total 279152 402083
Table 5 Observed distribution of invasive cancers by screening frequency for women, age 50–74 years, screened over 2 years either annually or
biennially
Mode of detection
Number
of cases
observed
Number
at risk
a
Observed
rate per 100000
Weighting of
cancers by mode
of detection (%)
Annual screening prior to 1997
Screen detected at 10–14 months 438 188709 232 76.6
Interval cancers p12 months 305 428574 71 23.4
Biennial screening after 1997
Screen detected at 20–28 months 692 208723 332 58.8
Interval cancers p12 months 351 439550 80 14.1
Interval cancers 12–24 months 384 250979 153 27.1
aFor screen-detected cancers, unit is the number of screens; for interval cancers, unit is person-years.
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Figure 1 Breast cancer-specific survival rate for 5844 women ever
attending SMPBC and subsequently diagnosed with unilateral invasive
breast cancer, 1988–2002.
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cancer mortality for the relevant prognostic factors are provided in
Table 1. The observed distribution of prognostic factors for the
2441 cancer cases in the screening sample is shown in Table 2. The
prognostic profile of screen-detected cancers was better than that
of interval cancers, while the profile of screen-detected cancers was
similar for those found at the ‘annual’ or the ‘biennial’ screen. This
was also true for interval cancers diagnosed between 0–12 and
12–24 months. This similarity in prognostic factors translated into
minimal differences in estimated 5- and 10-year breast cancer-
specific survival rates for each type of tumour, as calculated using
the prognostic model developed from the ‘prognostic sample’ and
prognostic factors in the ‘screening sample’ (Table 3).
The distribution of screening intervals is shown in Table 4, the
mean interval for those screened prior to 1997 being 12.4 months
compared to 24.1 months for those screened after 1997.
Approximately two-thirds of the screening intervals prior to
1997 were 10–14 months, whereas only 20% of those after 1997
were of that length, coincident with the change in SMPBC policy.
Approximately half the screening intervals after 1997 were 20–28
months. The age distribution of women aged 50–74 years was
similar for the two periods, with means of 61.0 years prior to 1997
and 61.2 years after 1997.
Of those included in the screening sample, the likelihood of
having a screen-detected cancer diagnosed with an ‘annual’
screening interval prior to 1997 was 2.32 per thousand screens
(438 out of 188709) and for women with a ‘biennial’ screening
interval after 1997 was 3.32 (692 out of 208723). The rate of
interval cancer by time since last screen was similar over the first
12 months after a screen before 1997 (0.71 per 1000) and after 1997
(0.80 per 1000). The cumulative rate of interval cancers by 24
months was 2.33 per 1000 after 1997. The resulting estimated
numbers of screen-detected and interval-invasive cancers per
100000 women screened and per 100000 person-years, respec-
tively, for a period of 2 years, either ‘annually’ before 1997 or
‘biennially’ after 1997 are given in Table 5. The overall numbers of
invasive and in situ cancers predicted over the 24 months were
very similar (716 vs 713) for the two screening frequencies, but
more tumours were in situ in the post-1997 period.
Based on the distribution of screen-detected and interval
cancers for the two screening strategies, the estimated breast
cancer-specific survival rates for women aged 50–74 years
undergoing annual as compared to biennial screening mammo-
graphy were 95.2 and 94.6%, respectively, at 5 years, and 90.4 and
89.2%, respectively, at 10 years (Table 6). The absolute difference
in estimated breast cancer survival between the annual and
biennial screening strategies were 0.6% at 5 years and 1.2% at 10
years, corresponding to a relative risk of 0.89 in favour of annual
screening, assuming 100% compliance.
Figure 2 shows the Kaplan–Meier survival curves for all women
aged 50–79 attending the SMPBC, diagnosed with invasive,
unilateral breast cancer prior to and after 1997. There was no
difference in observed survival for patients diagnosed prior to or
after the policy change of annual to biennial screening for women
diagnosed with breast cancer after SMPBC attendance.
DISCUSSION
This large, retrospective, population-based study of women aged
50–74 has found that annual screening mammography was
associated with a higher proportion of screen-detected cancers
than was biennial screening. The distribution of cancers and
prognostic profiles translated into small absolute differences in
modelled 5- and 10-year breast cancer-specific survival in a
hypothetical cohort of 100000 screens performed either annually
or biennially (0.6 and 1.2%, respectively), in favour of the annually
screened group. In keeping with this, there was no difference in
observed survival in women diagnosed with ipsilateral, invasive
breast cancer undergoing screening mammography during the
time of an annual or biennial screening policy.
The predicted differences in 10-year breast cancer survival were
similar to the findings of the only randomised trial addressing this
issue, the United Kingdom Co-ordinating Committee on Cancer
Research Randomised Trial performed (Breast Screening Fre-
quency Trial Group, 2002). That study randomised women, aged
50–62 years, with a normal prevalent screen in the UK National
Health Services (NHS) Breast Screening Programme, to a
conventional incident screen after an interval of 3 years (control
arm) or to three annual screenings (study arm).
The BSFTG randomised trial found that the incidence of breast
cancers was 2.44 per thousand per annum in the study arm and
2.15 in the control arm, similar to the estimates from our study.
Also, 71% of the cancers were screen-detected in the annual recall
(study) arm compared to 50% in the 3-year recall (control) arm,
similar to the rates, 76% in the annual and 58% in biennial
screening cohorts found in this study. As expected, the shorter
screening interval was associated with a higher proportion of
screen-detected cancers, compared to interval cancers, but this
translated to only a small absolute difference in the estimated 10-
year breast cancer-specific survival: approximately 2% in the
randomised trial and 1% in the current study.
In a meta-analysis of data from the randomised trials, there was
no difference in the reduction in breast cancer mortality among
women aged 50–74 with planned screening intervals of less than
Table 6 Predicted 5- and 10-year survival rates by frequency of
screening
a
Screening
frequency
Predicted 5-year
survival rate (%)
Predicted 10-year
survival rate (%)
‘Annual’ 95.2 90.4
‘Biennial’ 94.6 89.2
aPredicted breast cancer-specific survival rates based on expected prognostic profile
and distribution of interval and screen-detected cancers.
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Figure 2 Observed survival curves for women aged 50–79 at screening
and diagnosed with breast cancer prior to 1997 (annual screening period)
or after 1997 (biennial screening period). Cases prior to 1997 were either
interval cases p12 months or screen-detected at 10–14 months; those
diagnosed after 1997 were either interval cases p24 months or screen-
detected at 20–28 months.
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months (Kerlikowske et al, 1995).
Computer modelling simulations suggest that breast cancer
mortality reductions improve with shorter screening intervals,
with improvements as much as from 26%, for mammography
performed every 5 years, to 66%, annual mammography (Szeto
and Devlin, 1996; Michaelson et al, 1999, 2000; Fett, 2001). In
contrast, Jansen et al used modelling to show that shorter
screening intervals may be associated with greater detection of
‘excess’ tumours that would not have been detected before the
subject died of other causes, and that the overall benefit to the
population with respect to breast cancer mortality was greater
when a larger proportion of the population were screened at a
lower frequency compared to a smaller proportion screened more
frequently (Jansen and Zoetelief, 1997).
Retrospective studies comparing interval and screen-detected
cancers have shown that interval cancers are similar to cancers in
unscreened women, and that screen-detected cancers generally
have better prognostic indicators, with smaller tumours, fewer
node-positive tumours, and a larger proportion of in situ tumours
(Burrell et al, 1996; Porter et al, 1999). The current study confirms
these observations, but of note is the similarity of the prognostic
profile of interval cancers for those screened annually and that of
interval cancers in those screened biennially, with the same being
true for screen-detected cancers.
Retrospective cohort studies that examined prognostic differ-
ences of tumours detected in women who self-selected different
screening frequencies have generally shown that those screened
less frequently have tumours with worse prognostic profiles,
including larger tumour size, more lymph node metastases, and
fewer cases of isolated in-situ disease (Gabriel et al, 1997; Field
et al, 1998; Carlson et al, 1999; Hunt et al, 1999). It has been shown
that the higher absolute rate of false-positive screens increased
with more frequent screening (Elmore et al, 1998).
A limitation of the current study is that, during the study
interval (1995–2002), there could have been improvements in the
technical aspects of imaging or in radiologist experience that may
have affected detection rates (Kan et al, 2000; Feig, 2002; Haus,
2002; Taplin et al, 2002), although SMPBC data suggest that
improved detection is unlikely to explain our observations. Within
the SMPBC, women, aged 40–49, were recalled for screening
annually both before and after 1997 and comparison of these
periods showed little difference, with the cancer detection rate
increasing only 0.1 per 1000 for both first and subsequent screens
after 1997 (SMPBC unpublished data, December 2003). Another
limitation was the incomplete enforcement of the change in
screening policy with some women not following the re-screening
recommendations in each period. This necessitated a wider range
of duration between screens in the era after 1997 to create
comparably sized groups for analysis purposes.
In spite of these limitations, this study provides useful
information about different screening intervals based on actual
data from a large, population-based screening programme that
instituted a policy change, in the modern era of two-view, film-
screen mammography. Complete and accurate outcome data were
obtained through direct linkage to the provincial cancer registry.
The two comparison groups were selected to minimise selection
bias. The predicted survival was based on a prognostic model that
used cases over the whole period to avoid the survival effect of
changes in treatment between the different periods. Thus, the
predicted survival was a ‘blended’ rate of the survival in each
period and was applied uniformly to everyone in the study
regardless of her date of diagnosis.
In conclusion, this study has shown that annual screening
mammography minimally improved the estimated breast cancer
survival rates for women aged 50–74 years, as compared to
biennial screening at 5 and 10 years, with an absolute projected
survival difference of 0.6% at 5 years and 1.2% at 10 years for those
women diagnosed with breast cancer.
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